Stem Cell Therapy for Chronic Kidney Disease

Recruiting at 1 trial location

Overseen By Latonya Hickson

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: LaTonya J. Hickson

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 0

10 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing if using donor stem cells is safe and tolerable for people with chronic kidney disease. The stem cells might help repair their damaged kidneys. Stem cell therapy has shown potential in treating kidney diseases and aiding in kidney regeneration.

Research Team

LaTonya Hickson, MD

Principal Investigator

Mayo Clinic

Eligibility Criteria

This trial is for adults aged 30-80 with chronic kidney disease, specifically those not on dialysis or with a transplant history. Participants must have certain levels of kidney function and protein in their urine, and can't be pregnant, heavy smokers, drug users, or have uncontrolled diseases like severe anemia.

Inclusion Criteria

Ability to give informed consent

I am between 30 and 80 years old.

Your kidney function, as measured by eGFR, is between 25 and 55 ml/min/1.73m^2.

Exclusion Criteria

I am unable to understand and give consent for treatment.

I currently have an infection.

I have liver cirrhosis.

Treatment Details

Interventions

• Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion
• Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions

Trial Overview The study tests the safety of using stem cells from fat tissue to treat chronic kidney disease. Patients will receive either one or two infusions of these cells to see how well they tolerate them and any potential benefits.

Participant Groups

Group I: Dose Arm 2 Experimental Treatment 1 Intervention

Subjects with chronic kidney disease will receive a single intravenous infusion of allogeneic adipose tissue-derived mesenchymal stem cells (MSC) of 150x10\^6 cells at day 0.

Group II: Dose Arm 1 Experimental Treatment 1 Intervention

Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75x10\^6 cells at day 0 and month 3.

Who Is Running the Clinical Trial?

LaTonya J. Hickson

Lead Sponsor

Trials

2

Recruited

20+